Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

What do patients and doctors really think about prolactinoma care?

NCT ID NCT06936813

Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study surveys 530 prolactinoma patients and their doctors to understand real-world treatment experiences, side effects, and preferences. The goal is to identify gaps in care and guide future research for better, more personalized treatment strategies. No new treatments are tested; it is purely an information-gathering study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

530 people

The number who actually took part.

Started

Jun 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prolactinoma patients and physicians involved in the management of prolactinomas. Survey will be accessible globally via online patient communities, pituitary disorder organizations, physician networks, and in-clinic distribution.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prolactinoma patients * Prolactinoma treating physicians including endocrinologists and neurosurgeons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pituitary tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pituitary Neoplasms pituitary tumor prolactin-producing pituitary gland adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pituitary tumor Prolactinoma

Contacts and locations

Locations

  • University Hospital Basel

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.